Specialty Pharmacy

A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.

Epidiolex was approved to treat seizures associated with 2 rare and severe forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—in patients aged 2 years and older.

Based on evidence from a systematic review, researchers are calling for increased access to lifesaving hepatitis C treatments for injection drug users.

Top news of the day from across the health care landscape.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.

Latest approval for carfilzomib offers a more convenient dosing option for patients with multiple myeloma.

A high-touch patient care model with enhanced data collection may help stop the ongoing opioid problem.

Top news of the day from across the health care landscape.

According to FDA Commissioner Scott Gottlieb, MD, the agency’s approval of amikacin liposome inhalation suspension marks an important policy milestone.

Lymphatic vessels surrounding the brain may play a key role in the development and progression of multiple sclerosis.

Luis Torres, MBA, Vice President, Managed Care, BioPlus Specialty Pharmacy, discusses how collaboration between health care stakeholders is necessary to further the push towards a system that revolves around the patient.

Cemiplimab-rwlc (Libtayo) is the first and only treatment specifically approved and available for advanced cutaneous squamous cell carcinoma in the United States.

The FDA has expanded the indication of the antiepileptic drug perampanel (FYCOMPA, Eisai) CIII for monotherapy and adjunctive use in pediatric patients aged 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Dacomitinib (Vizimpro, Pfizer) is indicated for patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Galcanezumab-gnlm (Emgality), a once monthly, self-administered 120-mg subcutaneous injection, is indicated for the preventive treatment of migraine in adults.

Top news of the week from Specialty Pharmacy Times.

Entrectinib showed a durable response and reduced tumors in patients with ROS1-positive non-small cell lung cancer.

Top news of the day from across the health care landscape.

A look at last week's top stories in the world of pharmacy.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

A combination regimen of a CTLA4 targeted therapy and a PD-1 targeted therapy could be beneficial in treating ovarian cancer.

Top news of the day from across the health care landscape.

A federal bill that would lift ‘gag clauses’ prohibiting pharmacists from sharing prescription drug prices with customers was unanimously passed by the House of Representatives Tuesday.

Several hurdles remain for biosimilars to flourish in the US market.

How the re-emergence of social media tribes has shifted patient expectations of specialty pharmacy communication

In this video, Gordon Vanscoy, PharmD, MBA, CEO of PANTHERx Specialty Pharmacy explains the significance of patient centered care at PantheRx and in specialty pharmacy as a whole.

Majority of older patients with cancer and those who survived the disease found to have high levels of social and psychological wellbeing.

A pair of new studies is shedding light on a rare, but scientifically important, group of people with HIV who are able to maintain viral control even after stopping antiretroviral therapy.

Officials with Gilead Sciences, Inc. plan to launch authorized generic versions of Epclusa and Harvoni.

The US Preventive Services Task Force recommends against routine screening for prostate cancer in men 70 years of age and older.